A phase I trial showed promising antitumor capacity and manageable safety profile of CT017 CAR T cells (cells engineered to co-express GPC3 and RUNX3, a trigger of CD8+ T cell infiltration) in patients with advanced HCC [101]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.